Form 4: Pliant Therapeutics Director John Curnutte Granted 30,000 Stock Options

Pliant Therapeutics, Inc. Director John T. Curnutte was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year.

Summary

• John T. Curnutte, a Director of Pliant Therapeutics, Inc. (PLRX), was granted 30,000 derivative securities in the form of stock options.
• The transaction date for this grant was June 5, 2025.
• Each option has an exercise price of $1.61 per share.
• The options have an expiration date of June 5, 2035.
• The vesting schedule for these options is as follows: 25% vest on October 1, 2025; 25% vest on January 1, 2026; 25% vest on April 1, 2026; and the remaining 25% vest on the earlier of the one-year anniversary of the June 5, 2025 grant date or the next annual meeting of stockholders.
• Vesting is contingent upon Mr. Curnutte's continued service as a Director to the Issuer through each respective vesting date or annual meeting.
• Following this transaction, Mr. Curnutte beneficially owns 30,000 derivative securities.
• A Limited Power of Attorney was executed by John Curnutte on June 5, 2025, appointing specific individuals (Keith Cummings, Johannes Hull, Jennifer Woo, and Scott Peters) as attorneys-in-fact to execute and file SEC forms on his behalf.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is a positive for aligning management incentives with shareholder interests. It does not contain any negative news or significant risks beyond the standard conditions of such grants.

Positives

• The grant of stock options to Director John T. Curnutte aligns his interests with those of shareholders, incentivizing long-term performance and retention.
• The options have a long expiration date of June 5, 2035, providing a significant window for potential value realization.

Risks

• The vesting of the stock options is subject to the Reporting Person's continued service to the Issuer as a Director, meaning the options could be forfeited if service ceases before full vesting.

Future Outlook

The document outlines a future vesting schedule for the granted stock options, with portions becoming exercisable on October 1, 2025, January 1, 2026, April 1, 2026, and the remaining portion on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, subject to continued service.

Management Comments

• "/s/ Jennifer Woo, attorney-in-fact" Signature indicating the filing was made by an authorized attorney-in-fact on behalf of John Curnutte.

Industry Context

This Form 4 filing is a routine disclosure of an equity grant to a director in the biotechnology/pharmaceutical industry. Such grants are common practice for executive and director compensation, aiming to align leadership interests with company performance and shareholder value.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across the biotechnology and pharmaceutical sectors, aligning with typical corporate governance structures.
• The vesting schedule, which spans approximately one year with quarterly and annual milestones, is a common approach to incentivize continued service and long-term commitment, comparable to practices at companies like Gilead Sciences or Amgen for director equity awards.

Corporate Governance

Related Party Transactions

• The grant of stock options to John T. Curnutte, a Director of Pliant Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: While not directly impacting general employees, such compensation practices for leadership can contribute to overall company stability and strategic direction, indirectly benefiting employees.

Next Steps

• The vesting of 25% of the options on October 1, 2025.
• The vesting of 25% of the options on January 1, 2026.
• The vesting of 25% of the options on April 1, 2026.
• The vesting of the remaining 25% of the options on the earlier of the one-year anniversary of the grant date (June 5, 2026) or the next annual meeting of stockholders.

Key Dates

Keywords

Pliant Therapeutics, PLRX, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Vesting Schedule, Biotechnology, Pharmaceuticals